Kamada Ltd. (TLV:KMDA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 1.40B +1.0% |
| Revenue (ttm) | 571.54M +13.2% |
| Net Income | 66.29M +17.0% |
| EPS | 1.13 +19.0% |
| Shares Out | 57.69M |
| PE Ratio | 21.39 |
| Forward PE | 16.13 |
| Dividend | 0.75 (2.95%) |
| Ex-Dividend Date | Aug 27, 2026 |
| Volume | 78,102 |
| Open | 2,539.00 |
| Previous Close | 2,533.00 |
| Day's Range | 2,420.00 - 2,539.00 |
| 52-Week Range | 1,956.00 - 2,890.00 |
| Beta | 0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 12, 2026 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Full Company ProfileFinancial Performance
In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.
Financial numbers in USD Financial StatementsNews
Kamada Declares Cash Dividend of $0.17 Per Share; The Company Reported Record-High Revenue and Profitability for First Six Months of 2026
Dividend to be Paid Consistent with the Company's Cash Dividend Policy Dividend to be Paid Consistent with the Company's Cash Dividend Policy
Kamada CFO Chaime Orlev to depart
Kamada (KMDA) announced that Chaime Orlev, its CFO, will transition out of his role to pursue other opportunities, effective December 31. Kamada has a search underway to identify a successor…
Kamada reports Q2 EPS 16c, consensus 11c
Reports Q2 revenue $54.92M vs. $44.75M last year. “We continue to execute on our plan delivering record-high operational and financial performance during the first half of 2026, with strong double-dig...
Kamada backs FY26 revenue view $200M-$205M
The company said, “Kamada (KMDA) is reiterating its 2026 annual financial guidance of total revenues in the range of $200 million to $205 million, and adjusted EBITDA in the range…
Is Kamada (KMDA) a Solid Growth Stock? 3 Reasons to Think "Yes"
Kamada (KMDA) possesses solid growth attributes, which could help it handily outperform the market.
Kamada Q2 Earnings Call Highlights
Kamada NASDAQ: KMDA reported record revenue and adjusted EBITDA for the second quarter and first half of 2026, driven by higher sales of its specialty plasma-derived products, including KEDRAB, VARIZI...
Kamada Q2 2026 EPS Tops Expectations, Revenue Up 23%
Strong beat. Kamada Ltd. (NASDAQ:KMDA) delivered Q2 2026 adjusted earnings of $0.24 per share, more than doubling the $0.11 consensus estimate in a beat by ... The post Kamada Q2 2026 EPS Tops Expecta...
Kamada Earnings Call Transcript: Q2 2026
Record first-half 2026 results with double-digit revenue and EBITDA growth, driven by strong U.S. and international sales, expanding plasma operations, and disciplined cost management. Guidance for 2026 is reiterated, with continued double-digit growth expected.
Kamada Earnings release: Q2 2026
Kamada released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Kamada Releases Q2 2026 Financial Results
Kamada Ltd. The post Kamada Releases Q2 2026 Financial Results first appeared on Alphastreet .
Kamada (KMDA) Q2 Earnings and Revenues Surpass Estimates
Kamada (KMDA) delivered earnings and revenue surprises of +33.33% and +6.39%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance
REHOVOT, Israel and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for r...
Kamada Announces Planned Transition of Chief Financial Officer
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Earnings To Watch: Kamada Ltd (KMDA) Q2 2026 -- GF Value Sees 32% Upside
Earnings To Watch: Kamada Ltd (KMDA) Q2 2026 -- GF Value Sees 32% Upside
Curious about Kamada (KMDA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Kamada (KMDA) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for ...
Kamada to Announce Second Quarter and First Half Ended June 30, 2026 Financial Results on August 12, 2026
REHOVOT, Israel, and HOBOKEN, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada (KMDA) Secures $50M Plasma Supply Agreement
Kamada (KMDA) Secures $50M Plasma Supply Agreement
Kamada enters $50M sales agreement to supply plasma to biopharmaceutical company
Kamada (KMDA) announced an agreement to supply plasma to a biopharmaceutical company focused on plasma-derived therapies. The new three-year agreement for the supply of normal source plasma from Kamad...
Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived Therapies
REHOVOT, Israel and HOBOKEN, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference
Kamada (KMDA) Presents Promising Cytogam Study Results at Global Conference
Kamada highlights Cytogam study results
Kamada (KMDA) highlighted results of an Investigator-Initiated Study recently presented at the 2026 International Society for Heart and Lung Transplant annual meeting, held in Toronto, Canada. The stu...
Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting
Findings from analyses of CMV high-risk lung transplant recipients suggest CYTOGAM use is associated with improved clinical outcomes, supporting increased CYTOGAM utilization Findings from analyses of...
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test
Kamada (KMDA) Receives FDA Nod for New Fluorescent Focus Inhibition Test
Kamada Receives FDA Approval For In-House Rabies Virus Neutralization Testing Laboratory
(RTTNews) - Kamada Ltd. (KMDA), a biopharmaceutical company specializing in plasma-derived therapies, announced that the U.S. FDA has approved its new in-house rabies virus neutralization testing labo...
Kamada gets FDA approval for Rapid Fluorescent Focus Inhibition Test laboratory
Kamada (KMDA) announced FDA approval of the company’s new in-house Rapid Fluorescent Focus Inhibition Test, or RFFIT, laboratory. The new laboratory is part of Kamada’s Quality Control laboratory netw...